Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | CDK4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer

Cynthia X. Ma • 9 Jun 2020
ASCO 2020
Breast Cancer Abemaciclib Everolimus Exemestane Palbociclib Ribociclib
PACE TRINITI-1

Cynthia X. Ma, MD, PhD, Washington University School of Medicine, St. Louis, MI, updates us on recent understanding of potential resistance mechanisms to CDK4/6 inhibitors and therapeutic strategies for hormone receptor-positive (HR+) and HER2-negative (HER2-) metastatic breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Cynthia X. Ma

3:44
ALTERNATE: neoadjuvant endocrine treatment in ER+/HER2- breast cancer
Cynthia X. Ma • 7 Dec 2021
1:01
FLEX: real-world data platform bringing precision medicine to the clinic
Cynthia X. Ma • 7 Dec 2021
1:55
Predictive biomarkers in breast cancer
Cynthia X. Ma • 7 Dec 2021
3:01
ALTERNATE: neoadjuvant chemotherapy in ER+ HER2- breast cancer
Cynthia X. Ma • 3 Dec 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals